Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) is a preclinical-stage biotechnology company developing small-molecule therapeutics for aging and age-related diseases. Its lead candidate, orally administered Telomir-1, is designed to regulate intracellular metal balance, including iron, copper, calcium and zinc, and is… From the company’s description.
In fiscal 2025, Telomir Pharmaceuticals, Inc. reported a net loss of $10.41M. Operations used $3.69M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Telomir Pharmaceuticals, Inc. does
In the company’s own words
Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) is a preclinical-stage biotechnology company developing small-molecule therapeutics for aging and age-related diseases. Its lead candidate, orally administered Telomir-1, is designed to regulate intracellular metal balance, including iron, copper, calcium and zinc, and is being studied for effects on oxidative stress, mitochondrial function, epigenetic regulation and telomere integrity. The company is evaluating the compound in preclinical models across potential applications including Wilson’s disease, Type 2 diabetes, cancer, age-related macular degeneration and accelerated aging; it has not conducted human clinical trials. Telomir licenses U.S. rights to develop Telomir-1 for human and animal uses and has a pending merger with TELI Pharmaceuticals intended to bring the worldwide intellectual property portfolio and development programs under one company. It works with outside research, manufacturing and laboratory organizations to support its studies and development. Telomir reported no revenue for fiscal 2025. Its website is www.telomirpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MIAMI, FL
- Fiscal year end
- December
- CIK
- 1971532
- SIC
- 2834
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Telomir Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Telomir Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Telomir Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Telomir Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Telomir Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”